DGAP-News: Raptor Pharmaceutical Corp. Submits New Drug Application for RP103 for the Potential Treatment of Nephropathic Cystinosis
Raptor Pharmaceutical Corp.
30.03.2012 17:44
—————————————————————————
NOVATO, Calif., 2012-03-30 17:44 CEST (GLOBE NEWSWIRE) —
Raptor Pharmaceutical Corp. (–Raptor– or the –Company–) (Nasdaq:RPTP) announced
that it submitted a New Drug Application (–NDA–) to the U.S. Food and Drug
Administration (–FDA–) seeking approval to market its investigational drug
candidate, Cysteamine Bitartrate Delayed-release Capsules (RP103), for the
poten
